Abstract
BackgroundHigh-dose IL-2 is an FDA-approved immunotherapy that produces durable remissions in patients with melanoma and renal cell carcinoma (RCC) but is hampered by toxicities arising from peripheral immune activation. To...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
